Users of this system, can login to view this document.
Login
Enter the following information to request a copy of the document from the responsible person.
BEECH: a dose-finding run-in followed by a randomised phase II study assessing the efficacy of AKT inhibitor capivasertib (AZD5363) combined with paclitaxel in patients with estrogen receptor-positive advanced or metastatic breast cancer, and in a PIK3CA mutant sub-population.
This email address is used for sending the document.